Tang Capital Management LLC Buys New Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA)

Tang Capital Management LLC acquired a new stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 550,000 shares of the biotechnology company's stock, valued at approximately $9,432,000. Tang Capital Management LLC owned 0.23% of ADMA Biologics at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. Barclays PLC raised its stake in ADMA Biologics by 192.2% in the 3rd quarter. Barclays PLC now owns 528,629 shares of the biotechnology company's stock valued at $10,567,000 after acquiring an additional 347,692 shares during the period. Perpetual Ltd purchased a new position in shares of ADMA Biologics in the fourth quarter worth about $62,300,000. Nisa Investment Advisors LLC increased its stake in shares of ADMA Biologics by 133.9% in the fourth quarter. Nisa Investment Advisors LLC now owns 7,378 shares of the biotechnology company's stock worth $127,000 after purchasing an additional 4,224 shares in the last quarter. Veracity Capital LLC raised its position in shares of ADMA Biologics by 117.0% in the fourth quarter. Veracity Capital LLC now owns 46,415 shares of the biotechnology company's stock valued at $796,000 after purchasing an additional 25,030 shares during the period. Finally, KBC Group NV lifted its stake in shares of ADMA Biologics by 53.6% during the 4th quarter. KBC Group NV now owns 10,063 shares of the biotechnology company's stock valued at $173,000 after buying an additional 3,513 shares in the last quarter. Institutional investors own 75.68% of the company's stock.

ADMA Biologics Price Performance

NASDAQ ADMA traded down $0.32 during trading on Wednesday, reaching $20.12. The company's stock had a trading volume of 2,405,413 shares, compared to its average volume of 3,702,822. The stock has a market capitalization of $4.80 billion, a PE ratio of 71.86 and a beta of 0.57. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The firm has a fifty day moving average of $20.61 and a 200 day moving average of $18.90. ADMA Biologics, Inc. has a one year low of $9.35 and a one year high of $25.67.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). The business had revenue of $114.80 million during the quarter, compared to the consensus estimate of $116.40 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. ADMA Biologics's revenue was up 40.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.08 earnings per share. Analysts expect that ADMA Biologics, Inc. will post 0.51 EPS for the current fiscal year.

Analysts Set New Price Targets

ADMA has been the topic of a number of analyst reports. Cantor Fitzgerald reissued an "overweight" rating and set a $25.00 target price on shares of ADMA Biologics in a report on Tuesday, March 4th. StockNews.com cut ADMA Biologics from a "hold" rating to a "sell" rating in a report on Friday, May 9th. Finally, Raymond James increased their price objective on ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a report on Thursday, May 8th. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $24.25.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.